8:00 – 8:15 am

MISSION, GOALS AND OBJECTIVES OF RAISE II

South Ballroom

RAISE Chairpersons: M. Edip Gurol (Neurology, MGH/HMS)
Marc Fisher (Neurology, BIDMC/HMS)

  8:15 – 10:05 am

SESSION 1: NOVEL DIAGNOSTICS AND THE USE OF AI IN STROKE PREVENTION 

South Ballroom

Co-Chairs: Dawn Kleindorfer (Neurology, U. Michigan), Cheryl Bushnell (Neurology, Wake Forest)

8:15–8:27: Using 12-leads EKG to Predict Afib and Other Conditions
Paul Friedman (Cardiology, Mayo Clinic, Rochester, MN)

8:27 – 8:39 Wearables for Stroke Prevention Research
Michael Gibson (Cardiology, BIDMC)

8:39 – 8:51 Long-term monitoring for AFib Detection
Tina Baykaner (Cardiology, Stanford)

8:51 – 9: 03 AI and Big Data in Stroke Prevention Research
Nassir Marrouche (Cardiac EP, Tulane Univ.)

09:03 – 09:15 Advances in Cardiac Imaging
Evin Yucel (Cardiology, MGH)

09:15 – 10:05 Discussion
Jose Merino (Neurology, Georgetown), TBA

  10:25 am– 12:15 pm

SESSION 2: PREVENTION OF ISCHEMIC AND HEMORRHAGIC STROKES IN ATRIAL FIBRILLATION

South Ballroom

Co-Chairs: Pooja Khatri (Neurology, University of Cincinnati), Clinton Wright (NINDS)

10:25 – 10:37 Factor XIa inhibitors in AFib
Carolyn Lam (Cardiology, Duke-NUS)

10:37 – 10: 49 Updates in Left Atrial Appendage Closure for Stroke Prevention in AFib
Mohit Turagam (Cardiac EP, NYC, NY)

10:49 – 11:01 Atrial Fibrillation Ablation and Stroke Risk
Vivek Reddy (Cardiac EP, NYC, NY)

11:01 – 11:13 Atrial Fibrillation and Cognitive Impairment 
Rebecca Gottesman (NINDS)

11:13 – 11:25 Incorporating Advances in AFib Treatment into Clinical Practice: Challenges and Opportunities
Edip Gurol (MGH/HMS, Boston, MA)

11:25 – 12:15 Discussion
Magdy Selim (Neurology, Harvard Medical School), TBA

  1:15 – 3:05 pm

SESSION 3: NEW DRUGS FOR STROKE PREVENTION

South Ballroom

Chairs:  Argye Hillis (Neurology, JHU), Michelle Johanssen (Neurology, JHU)

1:15 – 1:27 P2Y₁₂ inhibitors: When to Use? What Other Data Do We Need?
Greg Albers (Neurology, Stanford)

1:27 – 1:39 GLP-1 Receptor Agonists and SGLT-2 Inhibitors for Stroke Prevention
Eda Cengiz (Endocrinology, UCSF)

1:39 – 1: 51 All ESUS / “Atrial Cardiopathy” Studies Failed: Now What?

Mitch Elkind (AHA)

1:51 – 2: 03 Updates on Management of Hyperlipidemia for Stroke Prevention
Seemant Chaturvedi (Neurology, University of Maryland)

2:03 – 2:15 How to design a trial to achieve FDA approval for a new indication
Andrew Farb (FDA)

2:15 – 3:05 Discussion
Hooman Kamel (Neurology, Cornell), Luciano Sposato (Canada), TBA

  3:20 – 5:10 pm

SESSION 4: NOVEL DEVICES FOR STROKE PREVENTION

South Ballroom

Co-Chairs:  Lauren Sansing (Neurology, Yale) , Scott Janis (NINDS)

3:20 – 3: 32 New/Potential Studies in PFO Closure
Jeff Saver (Neurology, UCLA)

3:32 – 3:44 Renal Denervation for Hypertension Control
Naomi Fisher (Endocrinology, BWH, Boston, MA)

3:44 – 3:56 Prophylactic Ablation and LAA Obliteration During Major Cardiac Surgery
DJ Lakkireddy (Cardiac EP, Kansas City)

3:56 – 4:08 Stroke During Major Endovascular Procedures & Emerging Protective Devices
Martin Leon (Cardiology, Columbia)

4:08 – 4:35 Special Lecture: FDA-approval process for drugs and devices: progress and challenges
Robert M. Califf (United States Commissioner of Food and Drugs)

4:35 – 5:10 Discussion
David Wang (Barrow Neurological Institute), TBA